Floatz logo

tamivarotene

Urothelial Carcinoma Recurrent

Nagoya UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

166 Active assets in the Urothelial Carcinoma Recurrent cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB

View all 50 →

Same molecule, other indications

tamivarotene is also rated in:

bladder transitional cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
urethra transitional cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →